$8.19

0.16 (1.99%)

5/22/2008 3:52 PM

ACADIA Pharmaceuticals, Inc. (ACAD)

CAPS Rating:

The Company is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule drugs for the treatment of central nervous system disorders.

Rating a stock in CAPS consists of three components:

Your call - Will this stock outperform or underperform the S&P 500? Successful picks are measured in terms of whether or not you were correct and by how many percentage points.

Your time frame - A guideline for other players to see whether your thinking is short or long-term. Time frame is also used to calculate the stock rating, but is not used in the scoring of your pick.

Your pitch - Here's your chance to offer more detailed thoughts, analysis, concerns, or the rationale behind your call. The pitch is optional and may be added later.

Each time you rate a stock, CAPS updates the community intelligence for the company, which may or may not change its CAPS rating. For more information, visit the Help tab at the top of the page.

You aren't currently rating ACAD

Add Stock to Watchlist

What the Community Thinks

Total Players

133 Outperforms

44 Underperforms

All-Stars

25 Outperforms

20 Underperforms

Wall Street

8 Outperforms

2 Underperforms

Players bullish on ACAD are also bullish on:

Players bearish on ACAD are also bearish on:

Ticker Tags

Micro Cap (4824), Biotechnology (292)
Suggest a tag

ACADIA Pharmaceuticals, Inc. At A Glance

Current Price:	$8.19
Last Trade Time:	5/22/2008 3:52 PM
Open:	$8.05
Previous Close:	$8.03
Daily Range:	$8.05 - $8.21
52-Week Range:	$7.63 - $17.33
Volume:	90,289
Market Cap:	$297.82M
P/E Ratio:	0.00
Compare Our Special Broker Offers!

Stock Trends

ACAD VS S&P 500 (SPY)

News & Discussion Boards

Sorry no news articles available for ACAD.

Top Bull Pitch

Recs

1 ACADIA Pharmaceuticals, Inc. (ACAD)

Avatar zzlangerhans (< 20) Submitted: 9/27/07 1:43 AM

I like the way this company is advancing its two major products aggressively. Positive catalysts within next year are interim data for phase III trial of pimavanserin and phase IIb trial of ACP-104. Company also has other drugs in early development.

Replies: 0 | Reply | Permalink

Top Bear Pitch

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches below!

CAPS Players

Show Me:

Sort by:

picks per page. CHANGE

Results 1 - 5 of 24 : 1 2 3 4 5 Next »

Recs 0 (ACAD) jmofield (64.49) Submitted: 5/13/08 6:51 PM : Start Price: $8.12 ACAD Score: -1.32 I have decided for the next serveral weeks to change my investment strategy to be short stocks trading between $1.50 and below $10 with a market cap of more than $100 million. My goal is to acheive at least a 60% sucess rate of beating the S&P Index. I am looking for 30% of my picks beating the S&P Index by more than 5% with an average per pick of at least 1.50. I am only looking to hold these positions for approximately 10-15 days. All the picks that I select are from screening criteria that I have developed using software from Vectorvest. I find it to be a good screening tool. For game playing purposes, since I always try to have 200 picks going at once, it's a shot gun approach with only short term trading in mind. Report this Post Replies: 0 \| Reply \| Permalink Oops! There appears to be a problem with your comment. Check to see if there's something you left out. Recs 0 (ACAD) psi21286 (83.22) Submitted: 4/25/08 3:51 PM : Start Price: $8.05 ACAD Score: 1.59 Who doesn't love pharmaceutical companies? They charge a fortune for their drugs and make huge profits. Risky if a drug loses FDA approval, but great if they get a cutting edge drug on th market. Report this Post Replies: 0 \| Reply \| Permalink Oops! There appears to be a problem with your comment. Check to see if there's something you left out. Recs 0 (ACAD) Cosmo21 (41.02) Submitted: 4/01/08 6:42 PM : Start Price: $9.38 ACAD Score: -14.47 ACAD is a strong buy at this level! Partnership on the way and the stock price will be back on it.s way to 17. Report this Post Replies: 0 \| Reply \| Permalink Oops! There appears to be a problem with your comment. Check to see if there's something you left out. Recs 0 (ACAD) bobby410 (< 20) Submitted: 12/04/07 5:35 PM : Start Price: $11.63 ACAD Score: -24.01 Have a friend who works there, & things are looking very very good. Report this Post Replies: 0 \| Reply \| Permalink Oops! There appears to be a problem with your comment. Check to see if there's something you left out. Recs 0 (ACAD) sdpowell (40.04) Submitted: 10/29/07 6:44 PM : Start Price: $15.16 ACAD Score: -37.01 huge potential for the drugs they offer, good chance of being acquired by a large company too Report this Post Replies: 0 \| Reply \| Permalink Oops! There appears to be a problem with your comment. Check to see if there's something you left out.
Results 1 - 5 of 24 : 1 2 3 4 5 Next »

Wall Street

Results 1 - 10 of 10

picks per page. CHANGE Expand All Pitches Collapse All Pitches

Top Pick	Player Name	Player Rating	Start Date	Call	Time Frame	Start Price	Stock Gain	S&P Gain	Score	Pitch
	TrackZacks	92.98	03/06/08		3M	$8.74	-6.41%	+6.49%	-12.89
	TrackBreanMurray	94.44	11/06/07		NS	$13.80	-40.72%	-7.49%	+33.23
	TrackLehmanBros	87.05	10/09/07		NS	$16.00	-48.94%	-10.28%	-38.66
	TrackDeutscheSec	89.78	08/21/07		NS	$15.00	-45.53%	-3.53%	-42.00
	TrackJimCramer	80.64	08/16/07		3W	$15.21	-46.29%	-1.84%	+44.45
	TrackFBR	86.66	07/10/07		NS	$13.65	-40.15%	-8.41%	-31.74
	TrackJMP	< 20	04/09/07		NS	$15.96	-48.81%	-3.52%	-45.29
	TrackRodmanRen	< 20	03/23/07		NS	$13.53	-39.62%	-2.65%	-36.97
	TrackFortisBank	98.61	02/23/07		NS	$7.89	+3.55%	-4.00%	+7.55
	TrackNeedham	< 20	12/14/06		NS	$9.19	-11.10%	-1.67%	-9.43
	TrackBofASec	94.50	08/15/06		NS	$5.74	+42.33%	+8.81%	+33.52

Results 1 - 10 of 10

Beat this Stock

Clicking "Beat this Stock!" will bring you to a company with a higher rating than the one you're currently viewing.

Even though CAPS shows only one- to five-star rankings, behind the scenes, all companies in CAPS have a distinct numerical ranking. In other words, there is a No. 1 stock in CAPS and a worst-ranked stock in CAPS. When you arrive at the top-ranked stock, clicking "Beat this Stock!" will cause the page to refresh.

That is, until there is a new No. 1 stock!

These companies do not represent formal Motley Fool recommendations. Please do your own due diligence before investing. Fool on.